子宫内膜异位症患者外周血及腹腔液中可溶性CD146的检测及临床意义

目的:检测子宫内膜异位症患者外周血及腹腔液中可溶性CD146(sCD146)水平并探讨其临床意义。方法:收集36例临床病理诊断明确的子宫内膜异位症患者和36例对照患者的血清及腹腔液,应用酶联免疫法(ELISA)检测血清及腹腔液sCD146的表达水平。结果:子宫内膜异位症患者外周血中sCD146的水平在整个月经周期(563.6±275.0)、增殖期(488.9±201.8)、分泌期(600.9±304.1)的表达均高于对照组的整个月经周期(376.2±133.5)、增殖期(351.9±81.9)、分泌期(410.3±183.5)的表达,差异有统计学意义(P<0.01)。子宫内膜异位症患者腹腔液中sCD146的水平在整个月经周期(844.1±264.1)、增殖期(1013.3±295.6)、分泌期(759.5±208.0)的表达均高于对照组的整个月经周期(536.4±221.1)、增殖期(564.9±237.0)、分泌期(496.6±202.1)的表达,差异有统计学意义(P<0.01);血清和腹腔液中两组分泌期和增殖期的表达均无统计学差异(P>0.05)。腹腔液各个周期的sCD146水平均高于外周血。结论:sCD146参与了子宫内膜异位症的发生和发展过程,无周期性的变化,表达较稳定。因此针对sCD146的检测和拮抗治疗很可能成为临床诊断和治疗该病的一种新途径。

Detection and clinical significance of soluble CD146 in peripheral blood and peritoneal fluid of patients with endometriosis

Objective:To detect the levels of soluble CD146 in peripheral blood and peritoneal fluid of patients with endometriosis,explore its clinical significance. Methods:The serum samples and peritoneal fluid samples from 36 patients diagnosed as endometriosis definitely(endometriosis group) and 360 cases without endometriosis(control group) were collected,ELISA was used to detect the expression levels of soluble CD146 in peripheral blood and peritoneal fluid. Results:The expression levels of soluble CD146 in peripheral blood of endometriosis group during the whole menstrual cycle,at proliferative phase and secretory phase were(563.6±275.0),(488.9±201.8)and(600.9±304.1),respectively,which were significantly higher than those in peripheral blood of control group during the whole menstrual cycle,at proliferative phase and secretory phase (376.2±133.5),(351.9±81.9) and(410.3±183.5),respectively](P<0.01).The expression levels of soluble CD146 in peritoneal fluid of endometriosis group during the whole menstrual cycle,at proliferative phase and secretory phase were(844.1±264.1),(1013.3±295.6) and(759.5±208.0),respectively,which were significantly higher than those in peritoneal fluid of control group during the whole menstrual cycle,at proliferative phase and secretory phase (536.4±221.1),(564.9±237.0) and(496.6±202.1),respectively](P<0.01).There was no significant difference in expression levels of soluble CD146 in peripheral blood and peritoneal fluid between proliferative phase and secretory phase(P>0.05).The expression levels of soluble CD146 in peritoneal fluid at proliferative phase and secretory phase were significantly higher than those in peripheral blood at proliferative phase and secretory phase. Conclusion:Soluble CD146 participates in the occurrence and development of endometriosis,without periodic change,and its expression is stable;targeted detection and antagonistic therapies may be a new pathway for clinical diagnosis and treatment of endometriosis.